Chargement en cours...
A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers
PURPOSE: Determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: Phase II study in adenoid cystic (ACC) and non-adenoid cystic (non-ACC) carcinomas. Gefitinib was administered 250mg oral...
Enregistré dans:
| Publié dans: | Head Neck |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5669372/ https://ncbi.nlm.nih.gov/pubmed/24585506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23647 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|